We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.
- Authors
Jagasia, M H; Abonour, R; Long, G D; Bolwell, B J; Laport, G G; Shore, T B; Durrant, S; Szer, J; Chen, M-G; Lizambri, R; Waller, E K
- Abstract
This prospective, randomized, double-blind, placebo-controlled study evaluated the efficacy of palifermin to reduce the incidence of severe (grade 3-4) acute GVHD after myeloablation and allo-SCT. Adults who received allo-SCT for hematologic malignancies received placebo or palifermin 60 μg/kg daily on three consecutive days before conditioning and a single dose of 180 μg/kg after conditioning, but often 1 or 2 days before allo-SCT. Subjects received MTX (plus CYA or tacrolimus) on days 1, 3, 6 and 11. Acute GVHD was evaluated once weekly and oral mucositis was evaluated daily. Subjects were randomly assigned to placebo (n=78) or palifermin (n=77). Conditioning included TBI in approximately half of the subjects (48% placebo, 51% palifermin). The primary efficacy end point, subject incidence of grade 3-4 acute GVHD, was similar between treatment groups (17% placebo, 16% palifermin). Grade 3-4 oral mucositis (73% placebo, 81% palifermin) and other secondary efficacy end points were similar between treatment groups. The most commonly reported treatment-related adverse events were skin/s.c. events such as rash, pruritus, and erythema. This exploratory study of acute GVHD after myeloablation and allo-SCT did not provide evidence of a treatment effect with this dosing regimen of palifermin.
- Subjects
GRAFT versus host disease; BLIND experiment; PLACEBOS; STEM cell transplantation; DRUG dosage; TACROLIMUS; THERAPEUTICS
- Publication
Bone Marrow Transplantation, 2012, Vol 47, Issue 10, p1350
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/bmt.2011.261